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Oxidation of lipid substrates is essential for survival
in fasting and other catabolic conditions, sparing
glucose for the brain and other glucose-dependent
tissues. Here we show Steroid Receptor Coactiva-
tor-3 (SRC-3) plays a central role in long chain fatty
acid metabolism by directly regulating carnitine/
acyl-carnitine translocase (CACT) gene expression.
Genetic deficiency of CACT in humans is accompa-
nied by a constellation of metabolic and toxicity
phenotypes including hypoketonemia, hypogly-
cemia, hyperammonemia, and impaired neurologic,
cardiac and skeletal muscle performance, each of
which is apparent in mice lacking SRC-3 expression.
Consistent with human cases of CACT deficiency,
dietary rescue with short chain fatty acids drastically
attenuates the clinical hallmarks of the disease in
mice devoid of SRC-3. Collectively, our results
position SRC-3 as a key regulator of b-oxidation.
Moreover, these findings allow us to consider plat-
form coactivators such as the SRCs as potential
contributors to syndromes such as CACT deficiency,
previously considered as monogenic.
INTRODUCTION
During fasting or prolonged exercise, mitochondrial fatty acid
metabolism is activated in skeletal muscle to protect glucose-
dependent tissues such as the brain. This metabolic switch in
skeletal muscle is controlled by tightly coordinated transcrip-
tional and allosteric regulatory events that prime the mitochon-
drial b-oxidation machinery for utilization of lipid substrates.
During periods of exertion when energy demand exceeds the752 Cell Metabolism 15, 752–763, May 2, 2012 ª2012 Elsevier Inc.mitochondrial capacity to deliver ATP, the muscle reverts to a
less efficient anaerobic pathway, eventually depleting the body
of glucose and forcing the cessation of exercise.
The mitochondrial b-oxidation system encompasses a set of
at least 25 enzymes and transport proteins to facilitate highly effi-
cient harvesting of energy from fatty acids (Eaton et al., 1996). To
date, deficiencies in 22 of these proteins have been directly
linked to a variety of human metabolic diseases (Moczulski
et al., 2009). While there are several points of regulation for fatty
acid metabolism, a critical step is the transport of fatty acids into
the mitochondria. This process is governed by the carnitine
transport system, where the enzymes carnitine palmitoyltrans-
ferase I and II (CPTI and CPTII) are functionally linked to the
activity of CACT, making this translocase a central regulator of
fatty acid metabolism (McGarry and Brown, 1997). Akin to other
defects in b-oxidation, deficits in CACT gene expression or
activity present as a constellation of clinical symptoms arising
from energy depletion and toxicity of accumulating lipid species
and other metabolites (Ro¨schinger et al., 2000; Rubio-Gozalbo
et al., 2004). Specifically, patients with CACT deficiency display
elevated plasma acyl-carnitines (AC), hypoketotic hypogly-
cemia, hyperammonemia, ventricular arrhythmia, seizures, and
progressive muscle weakness.
While the clinical manifestations of CACT deficiency have
been well documented, mechanisms that control CACT gene
expression remain poorly understood. Our current under-
standing is that metabolic adaptability of skeletal muscle is
achieved through transcriptional networks that coordinate
gene expression with fuel availability. Thus, transcription factors
including PPARa, PPARd, and FOXO along with coregulators
such as PGC-1a regulate skeletal muscle fatty acid metabolism
(Holloway et al., 2009). Another family of modulators with emer-
gent influence on metabolic transcriptional responses are the
Steroid Receptor Coactivators (SRCs) (York and O’Malley,
2010). The SRCs perform pleiotropic functions in diverse meta-
bolic processes such as glycogenolysis, gluconeogenesis, die-
tary fat absorption and lipid storage (York and O’Malley, 2010).
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obesity and improves peripheral insulin sensitivity, partly through
crosstalk with PGC-1a (Coste et al., 2008). Recent evidence also
suggests that functional impairment of the post-translational
modification code of SRC-3 is sufficient to impair whole body
metabolism (York et al., 2010). Although a number of studies
have identified clear metabolic roles for SRC-3, our under-
standing of the physiological mechanisms that control SRC-3
expression are currently incomplete. We do know that hepatic
SRC-3 gene expression is elevated upon fasting (Louet et al.,
2010), while in skeletal muscle, fasting appears to impose
a modest decrease in protein expression (Coste et al., 2008).
While these findings provide some elementary insight into
possible regulatory inputs for SRC-3 expression, they fail to
define how these physiological conditions impact SRC-3
activity.
To better understand how SRC-3 expression and activity
influence intermediary metabolism, we performed a comprehen-
sive metabolomics-based analysis to investigate how loss of
this central coactivator globally impacts metabolism in a tissue-
and pathway-specific manner. These data revealed a metabolic
signature that was unique to SRC-3 relative to SRC-1 or 2, and
specific to skeletal muscle. Expanding on these findings, we
provide evidence that SRC-3 is necessary for proper transport
and metabolism of long chain fatty acids, likely through the
regulation of CACT gene expression. Mice lacking SRC-3
display a marked deficiency in CACT expression, which is
accompanied by elevated long chain AC, hypoketonemia, hypo-
glycemia, cardiac abnormality, hyperammonemia, abnormal
electrical discharge in the brain, and severe muscle weakness,
all of which are phenotypes associated with CACT deficiency
in humans. Our studies therefore introduce another biological
player in the regulation of skeletal muscle fatty acid oxidation
that may contribute to unexplained disorders of lipid
homeostasis.
RESULTS
Ablation of SRC-3 Results in Accumulation of Long
Chain Fatty Acids
To better understand the unique tissue- and pathway-specific
metabolic functions of the SRC family of coactivators, we per-
formed a comprehensive metabolomics screen using mass
spectrometry on the core metabolic tissues (plasma, liver, and
skeletal muscle) from male SRC-1, SRC-2 and SRC-3 wild-
type and knockout littermate mice fed ad libitum or following
a 24 hr fast. A quantitative comparison of metabolites (amino
acids, organic acids and acyl-carnitines (AC)) revealed both
tissue- and pathway-specific phenotypes for the SRCs (Fig-
ure 1A). Interestingly, in SRC-3+/+ mice, a large increase is
observed in long chain AC in the skeletal muscle in the fasted
compared to the ad libitum fed state, consistent with increased
fatty acid availability and reliance on b-oxidation in this condition.
In contrast, long chain ACs are elevated in both the fed and
fasted states in SRC-3/ mice, such that these metabolites
accumulate in the fed state within the muscle of these animals
(Figures 1B and 1C). It is important to note that under fasting
conditions, both SRC-3+/+ and SRC-3/ mice show similar
high levels of muscle acyl-carnitines, as might be anticipatedCunder conditions where lipolysis is active. Normally, this condi-
tion results in a maximal rate of utilization of fatty acid substrates
by the muscle, which is observed in SRC-3+/+ mice as a sharp
drop in acyl-carntine levels in the fed compared to the fasted
state. Conversely, no such decrease is evident in the muscles
of SRC-3/ mice (Figure 1C). Moreover, the disruption of long
chain fatty acid metabolism observed in the absence of SRC-3
is mirrored for the short and medium chain AC, which also
show a lack of response to feeding in SRC-3/ mice (Fig-
ure S1A). Importantly, these effects were not observed upon
genetic deletion of either SRC-1 or SRC-2 (Figure S1B), suggest-
ing a unique role for SRC-3 in skeletal muscle.
Utilization of long and very long chain fatty acids relies on
a facilitated transport system, comprised of the mitochondrial
proteins CPT1, CACT and CPT2. Targeted qPCR screening of
muscle tissues taken from the same mice as used for metabolo-
mics analysis identified a significant reduction in CACT gene
expression in SRC-3/ compared to SRC-3+/+ mice (Figure 1D).
Interestingly, loss of SRC-3 conferred no alterations in 12 other
genes that are essential for fatty acid entry, transport, b-oxida-
tion, and ketogenesis (Table 1), suggesting CACT is a specific
target of SRC-3. To determine if other p160 family members
also regulateCACT gene expression, we analyzed its expression
in muscles of SRC-1 and SRC-2 null mice. Consistent with the
metabolomics data, loss of SRC-1 or SRC-2 did not significantly
influence CACT gene expression, suggesting SRC-3-specific
regulation of CACT in the muscle (Figure S1C). To demonstrate
that SRC-3 ablation leads to a substantial reduction of CACT
protein in the muscle in both the fed and fasted states, we per-
formedWestern blot analysis (Figures 1E and S1D) and immuno-
histochemistry (Figure 1F).
Loss of SRC-3 Resembles the Clinical Hallmarks
of Human CACT Deficiency
Mutations or insufficiency of the CACT gene result in clinical
symptoms of elevated long (and very long) chain fatty acids,
hypoketonemia, hypoglycemia, and muscle weakness. In
response to sustained exercise, when the demand for muscular
fatty acid metabolism is high, SRC-3 null animals showed
a marked reduction in plasma ketone concentration (Figure 2A),
suggesting an impairment of fatty acid oxidation in the skeletal
muscle. Hypoglycemia can occur as a consequence of the
inability to oxidize long chain fatty acids as the demand for
glucose metabolism increases. Consistent with this finding,
SRC-3 null animals are hypoglycemic under both refed and
fasted conditions (Figure 2B). We performed glucose and insulin
tolerance tests in SRC-3+/+ and SRC-3/mice, but observed no
clear differences in glucose homeostasis (Figure S2A). However,
hyperinsulinemic-euglycemic clamp studies revealed that
ablation of SRC-3 renders animals more insulin sensitive, as
indicated by the increased rate of glucose infusion required to
maintain euglycemia during the hyperinsulinemic clamp, and
increased whole-animal glucose disposal (Figures 2C and
S2B). Additionally, measurement of insulin levels during the
glucose tolerance test showed a reduction of insulin in SRC-3/
mice, further supporting an improvement in insulin sensitivity
(Figure S2A). Infusion of radiolabeled glucose in conscious
SRC-3+/+ and SRC-3/ mice identified muscle (gastroc and
soleus) as the primary driver of glucose uptake in the absenceell Metabolism 15, 752–763, May 2, 2012 ª2012 Elsevier Inc. 753
Figure 1. Loss of SRC-3 Leads to Muscle-Specific Accumulation of Long Chain Fatty Acids
(A) Venn diagram comparison of tissue-specific mass spectrometry-based metabolomics analyses of plasma, liver, and skeletal muscle amino acids, organic
acids and acyl-carnitines (AC) from SRC-1, SRC-2 and SRC-3 wild-type and knockout male mice (N = 5 each genotype). Of the total metabolites analyzed for
each tissue (plasma = 60; liver = 67; muscle = 77), the numbers of metabolites that are statistically changed (either increased or decreased) by comparing each
WT to its respective littermate knockout are indicated below the name of each coactivator (SRC-1, SRC-2, SRC-3). The number of statistically significant changes
(either increased or decreased) in metabolites shared by more than one coactivator is indicated in overlapping regions of the Venn diagram.
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Table 1. qPCR Analysis of Muscle Fatty Acid Regulatory Genes
Gene ID Gene Name SRC-3+/+ SRC-3/ p Value
CPT1b Carnitine Palmitoyltransferase I beta 0.703 ± 0.10 0.72 ± 0.10 0.93
CPT2 Carnitine Palmitoyltransferase 2 1.06 ± 0.09 0.91 ± 0.14 0.39
FASN Fatty Acid Synthase 7.53 ± 5.5 6.92 ± 5.1 0.94
MCD Malonyl-CoA Decarboxylase 1.16 ± 0.27 1.54 ± 1.17 0.31
ACC2 Acetyl-Coenzyme A Carboxylase beta 0.780 ± 0.09 0.754 ± 0.06 0.80
ACS Acyl-CoA Synthetase 1.20 ± 0.19 1.07 ± 0.23 0.67
ACADL Acyl-Coenzyme A Dehydrogenase, long chain 0.58 ± 0.07 0.60 ± 0.11 0.87
ACADVL Acyl-Coenzyme A Dehydrogenase, very long chain 1.15 ± 0.17 0.87 ± 0.10 0.20
ECHS1 Enoyl Coenzyme A Hydratase, short chain, 1, mitochondrial 1.11 ± 0.14 1.03 ± 0.07 0.65
HADH Hydroxyacyl-Coenzyme A Dehydrogenase 1.02 ± 0.12 0.88 ± 0.10 0.39
ACAA1A Acetyl-Coenzyme A Acyltransferase 1A 1.24 ± 0.11 1.16 ± 0.10 0.59
CRAT Carnitine Acetyltransferase 1.16 ± 0.27 1.54 ± 0.17 0.31
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depletion of hepatic and muscle glycogen stores and an accu-
mulation of neutral lipid (Figures S2C and S2D), likely resulting
from an inability to metabolize long chain fatty acids and prefer-
ential catabolism rather than storage of glucose in the SRC-3/
mice. Gene expression analysis of muscle from SRC-3+/+ and
SRC-3/ mice reveals a clear increase in hexokinases I and II
in the absence of SRC-3, supporting the compensatory increase
in glucose utilization in muscle (Figure 2D).
Deficiency of CACT enzymatic function in humans impairs
efficient b-oxidation of long (and very long) chain fatty acids,
creating a reliance on glucose metabolism and severely dimin-
ishing the capacity of muscle for prolonged exercise. To deter-
mine if a similar phenotype develops in mice lacking SRC-3,
SRC-3+/+ and SRC-3/mice were run to exhaustion on a tread-
mill using a program that will promote fatty acid metabolism.
Loss of SRC-3 dramatically reduces exercise capability (Fig-
ure 2E). Our prior studies have reported that SRC-3/ mice
have a reduction in total body mass (Xu et al., 2000; Xu and
O’Malley, 2002). To eliminate the possibility that the observed
reduction in run time of SRC-3/ mice was simply due to a
decrease in leanmusclemass, we performedDEXA (dual-energy
X-ray absorptiometry) analysis of SRC-3+/+ and SRC-3/ mice
(Figure S2E). Run times from Figure 2E were normalized for
lean muscle mass and revealed a similar reduction for SRC-3/
mice (Figure S2F), suggesting that the exercise deficiency arises
from dysfunction of themuscle, rather than a decrease in muscle(B) Heat map representation of z-score transformed raw data representing varyin
isolated from SRC-3+/+ (N = 5) and SRC-3/ (N = 5) mice fed ad libitum or followi
scale with blue representing low z-score values and red representing high z-sco
(C) Graphical representation of raw data from Figure 1B representing the sum (S) o
ad libitum (white bars) or following a 24 hr fast (black bars) as indicated.
(D) Quantitative real-time PCR analysis of CACT gene expression from skeletal m
ad libitum. Expression levels were normalized to 18S rRNA.
(E)Western blot analysis of CACT and a-tubulin protein expression in skeletal mus
ad libitum. Protein levels at each time point were quantitated by densitometry usi
under each lane. Data are graphed as the mean ± s.e.m.
(F) Representative histology of skeletal muscle isolated from SRC-3+/+ and SRC
immunohistochemistry for expression of either SRC-3 or CACT as indicated. Quan
are graphed as the mean ± s.e.m. *p < 0.05, ***p < 0.001 versus WT mice.
Cmass. Cytochemical analysis of muscles from SRC-3+/+ and
SRC-3/ mice shows a trend toward an increase in fast
twitch fiber type in the latter group (Figure S2G), which is
further supported by qPCR analysis of gene markers for
different fiber types (type I: Myh1; type IIa: Myh2; and type IIb:
Myh4) (Figure S2H). We propose that the impairment of SRC-3
null animals to efficiently metabolize long chain fatty acids
creates a demand for glucose by the skeletal muscle (as
observed by hyperinsulinemic-euglycemic clamp), which ulti-
mately drives a transition from a slow (fatty acid utilizing) to
a fast (glucose utilizing) twitch fiber type. To exclude the possi-
bility that altered lipid delivery to the skeletal muscle contributes
to these phenotypes, we analyzed plasma free fatty acids,
triglycerides, as well as skeletal muscle triglycerides from
SRC-3+/+ and SRC-3/ mice (Figure S2I). These data show no
significant differences in plasma free fatty acids or triglycerides,
but reveal an accumulation of muscle triglycerides that is consis-
tent with both our metabolomic and cytochemical analyses
(Figures 1B, 1C, and S2D).
To further investigate the impact of SRC-3 loss on metabolic
adaptability, we performed indirect calorimetry on SRC-3+/+
and SRC-3/ mice under the same exercise conditions utilized
in Figure 2E. Analysis of the respiratory quotient compiled into
quartiles of run time show an impaired ability of SRC-3/
mice to transition from carbohydrate to fatty acid utilization as
compared to SRC-3+/+ mice (Figure 2F). Additionally, we tested
home cage activity of SRC-3+/+ and SRC-3/ mice and foundg chain length AC obtained from mass spectrometry of skeletal muscle extract
ng a 24 hr fast as indicated. The heat map is set on a three-point gradient color
re values, respectively.
f all long chain species AC from SRC-3+/+ (N = 5) and SRC-3/ (N = 5) mice fed
uscle of SRC-3+/+ (white bars, N = 5) and SRC-3/ (black bars, N = 5) mice fed
cle protein extract isolated from SRC-3+/+ (N = 3) and SRC-3/ (N = 3) mice fed
ng Image J software and normalized to a-tubulin and are indicated numerically
-3/ mice fed ad libitum. Formalin fixed tissues sections were analyzed by
titation of the CACT signal was performed using Image Pro Plus software. Data
ell Metabolism 15, 752–763, May 2, 2012 ª2012 Elsevier Inc. 755
Figure 2. Ablation of SRC-3 Phenocopies the Primary Clinical Symptoms of CACT Deficiency
(A) Plasma profiling of b-hydroxybutyrate under resting (non-exercised) conditions or immediately following exhaustive exercise in SRC-3+/+ (N = 10) and
SRC-3/ (N = 10) mice.
(B) Measurement of blood glucose in SRC-3+/+ (N = 5) and SRC-3/ (N = 5) mice following 24 hr fasting or a 3 hr refeed after a 24 hr fast.
(C) Hyperinsulinemic/euglycemic clamp analysis of basal and clamped glucose production, glucose disposal rate, glucose infusion rate, and tissue-specific
(gastroc, soleus, WAT) glucose uptake measured in SRC-3+/+ (N = 7) and SRC-3/ (N = 7) mice.
(D) Quantitative real-time PCR analysis ofHK-1 andHK-2 gene expression levels in skeletal muscle of SRC-3+/+ (white bars, N = 5) and SRC-3/ (black bars, N =
5) mice fed ad libitum. Expression levels were normalized to 18S rRNA using the DDCT method where each gene is relative to its own internal 18S rRNA control
individually normalized against one SRC-3+/+ sample.
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SRC-3 Is Essential for Fatty Acid Metabolismno differences in basal activity of SRC-3+/+ and SRC-3/ mice
(Figure S2J), thus eliminating the possibility that the decreased
run time in SRC-3/micewas influenced by a reduction in basal
activity. Collectively, these data showed that loss of SRC-3
resembles the primary symptoms of CACT deficiency observed
in humans.
SRC-3–/– Mice Display Secondary Metabolic Defects
Resulting from CACT Deficiency
The primary metabolic effects of CACT gene deficiency related
to impairment of fatty acid oxidation give rise to a number of
secondary phenotypes, including hyperammonemia, cardiac
arrhythmia and seizures. While no consensus exists on the
etiology of the resulting hyperammonemia, two leading hypoth-
eses are increased proteolysis to provide the substrates for de
novo carnitine biosynthesis and impaired urea cycle function
(Ro¨schinger et al., 2000). Metabolomics analysis of plasma
from SRC-3+/+ and SRC-3/ mice shows that SRC-3 knockout
causes an increase in levels of 15 amino acids, with these
increases attaining statistical significance for 9 of the analytes
(Figures 3A and S3A). This global increase in circulating amino
acids is likely due to increased protein catabolism. The free
ammonia generated from protein catabolism is metabolized in
the liver via the urea cycle. Initiation of the urea cycle requires
N-acetylglutamate, which is synthesized from acetyl-CoA
and glutatmate. Metabolomics analyses of the livers of
SRC-3+/+ and SRC-3/ mice revealed a significant decrease
in acetyl-carnitine (representative of acetyl-CoA) along with a
concomitant increase in glutamate (Figure 3B). These findings
suggest that catabolism of amino acids is another compensa-
tory mechanism for overcoming the deficit in mitochondrial
fatty acid oxidation and hypoglycemia elicited by SRC-3
knockout, resulting in a high rate of transamination of amino
acids to yield glutamate (thus the rise in this analyte), and
a high rate of acetyl-CoA utilization to initiate the urea cycle
(thus the fall in this analyte). This concept is supported by clear
elevation in the urea cycle intermediates ornithine, citrulline,
and arginine in livers of SRC-3/ mice (Figure 3B). Moreover,
qPCR analysis of the key enzymes of the urea cycle shows
a marked elevation in the livers of SRC-3/ mice (Figure 3C),
consistent with increased levels of urea in the urine of
SRC-3/ mice (Figure 3D). Collectively, the apparent increase
in flux through amino acid catabolic pathways in SRC-3/
mice elicits an attempt to compensate by an increase in
urea cycle activity that is ultimately overwhelmed by high rates
of transamination and ammonia production, resulting in
hyperammonemia.
Abnormal systems metabolism affects fuel substrate avail-
ability to other metabolic organs. Two of these main organs,
the brain and heart, are inherently sensitive to changes in fuel
levels (Cunnane et al., 2011; Taegtmeyer et al., 2005). Echocar-
diogram (ECG) analysis of resting SRC-3+/+ and SRC-3/ mice(E) Treadmill endurance exercise measurements from SRC-3+/+ (white bars, N =
until exhaustion.
(F) Calculated respiratory quotients (VCO2/VO2) obtained from indirect calorimetr
N = 6)micewhile running on a 10 incline at 15m/min until exhaustion. Respiratory
quartiles. Data are graphed as the mean ± s.e.m. *p < 0.05, **p < 0.01, NS = not
Cexposed a variety of cardiac abnormalities elicited by loss of
SRC-3 (Figure 3E). Most notably, SRC-3 ablation leads to
decreased heart rate and overall disruption of the normal ECG
profile (Figures 3E, S3B, and S3C). Furthermore, electroenceph-
alography (EEG) analysis of SRC-3+/+ and SRC-3/ mice re-
vealed enhanced spontaneous discharge activity in the absence
of SRC-3, which suggests a higher susceptibility to seizure
(Figure S3D).
Symptoms Arising from Impaired Long Chain Fatty Acid
Metabolism in SRC-3–/– Mice Are Rescued by Dietary
Intervention with Short Chain Fatty Acids
Consistent with other long chain fatty acid disorders, the most
widely accepted therapy for treating CACT deficiency is dietary
supplementation of short andmedium chain fatty acids, coupled
with restricted intake of long (and very long) chain fatty acids (La-
foreˆt and Vianey-Saban, 2010; Wilcken, 2010). SRC-3+/+ and
SRC-3/ mice were placed on diets enriched in either short/
medium chain fatty acid (SCD) or long/very long chain fatty acids
(LCD) for 10 weeks. Body weight measurements made over the
10-week feeding period shows that SRC-3+/+ and SRC-3/
mice gain weight normally and independent of diet (Figure S4A).
SRC-3+/+ and SRC-3/ mice placed on SCD or LCD were sub-
jected to treadmill exercise under conditions used in Figure 2E.
These data demonstrate that SRC-3/ mice respond to SCD
with improved run times as compared to SRC-3+/+ littermates,
while on chow or LCD, SRC-3/ mice remain significantly
impaired (Figure 4A, left panel). It is important to note that consis-
tent with published data (Koonen et al., 2010), mice fed a SCD
show amarginal reduction in absolute run time resulting primarily
from the decreased energetic potential of short chain fatty acids
(Figure 4A, right panel). Indirect calorimetry of SRC-3+/+ and
SRC-3/ mice on SCD show no difference between groups in
RQ (Figure 4B), as compared to chow feeding, where the sepa-
ration between groups and metabolic inflexibility is clearly
apparent (Figure 2F). Importantly, the SCD diet also rescued
the hypoketonemia observed in SRC3/ mice on either normal
chow or LCD diets. LCD supplementation actually exacerbated
this condition (Figure 4C). Similarly, dietary intervention with
SCD in SRC-3/mice was sufficient to restore normoglycemia,
while feeding LCD resulted in a more severe hypoglycemic
condition (Figure 4D). Moreover, metabolomics data obtained
from SRC-3/ mice placed on SCD showed normalization of
long and very long chain AC profiles (Figure 4E) and overall
improvement of amino acid levels when compared to SRC-3+/+
mice (Figure 4F), while feeding a LCD resulted in AC and amino
acid profiles that closely resembled SRC-3/ mice on normal
chow (Figures S4B and S4C). Taken together, these findings
suggest that dietary supplementation of short/medium chain
fatty acids is sufficient to improve the majority of the clinical
symptoms arising from a deficit in CACT gene expression in
SRC-3/ mice.10) and SRC-3/ (black bars, N = 10) mice run on a 10 incline at 15 m/min
y measurements from SRC-3+/+ (white filled, N = 6) and SRC-3/ (black filled,
quotient data are graphed as a function of total run time broken into percentage
statistically significant versus WT mice.
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Figure 3. SRC-3–/– Mice Display Secondary Metabolic Defects Resulting from CACT Deficiency
(A) Quantitative mass spectrometric analysis of the sum of all plasma amino acids from SRC-3+/+ (white bars, N = 5) and SRC-3/ (black bars, N = 5) mice fed ad
libitum and graphed as mM.
(B) Quantitative mass spectrometric analysis of urea cycle metabolites (acetyl-carnitine, GLX (glutamate/glutamine), ornithine, citrulline, and arginine) from liver
tissue extracts isolated from SRC-3+/+ (white bars, N = 5) and SRC-3/ (black bars, N = 5) mice fed ad libitum.
(C) Quantitative real-time PCR analysis ofCPSI,ASS1, andOTC gene expression levels in liver tissue fromSRC-3+/+ (white bars, N = 5) and SRC-3/ (black bars,
N = 5) mice fed ad libitum. All expression levels were normalized to 18S rRNA.
(D) Quantitative colorimetric enzyme analysis of urine urea from SRC-3+/+ (white bars, N = 5) and SRC-3/ (black bars, N = 5) mice fed ad libitum.
(E) Non-invasive electrocardiography analysis of resting conscious SRC-3+/+ (white bars, N = 8) and SRC-3/ (black bars, N = 8) mice fed ad libitum. Data
presented are heart rate (beats per min), RR, PR, QT, ST and PQ intervals (milliseconds), respectively. Data are graphed as themean ± s.e.m. *p < 0.05, **p < 0.01,
***p < 0.001, NS = not statistically significant versus WT mice.
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in a Cell-Autonomous Manner
Despite the central importance of CACT in long chain fatty acid
metabolism, little is known regarding the regulation of CACT
gene expression. Our data establish that in vivo ablation of
SRC-3 leads to a significant reduction of CACT expression in
muscle. To investigate the mechanistic underpinnings of758 Cell Metabolism 15, 752–763, May 2, 2012 ª2012 Elsevier Inc.SRC-3 regulation of CACT gene expression, we performed
siRNA knockdown of SRC-3 in the mouse myoblast cell line,
C2C12 (Figure 5A). Knockdown of SRC-3 in C2C12 cells resulted
in a significant reduction of CACT gene expression (Figure 5B, i
and ii), supporting a cell-autonomous role for SRC-3.
To directly test the effect of SRC-3 on CACT expression, we
performed luciferase reporter gene assays using the CACT
Figure 4. Dietary Treatment with Short/Medium Chain Fatty Acids Rescues CACT Deficiency in the Absence of SRC-3
(A) Treadmill endurance exercise measurements from SRC-3+/+ (white bars, N = 10) and SRC-3/ (black bars, N = 10) mice run on a 10 incline at 15 m/min until
exhaustion following a 10-week regimen of normal chow (Chow), short chain fatty acid enriched diet (SCD) or long chain fatty acid enriched diet (LCD). Run time
data are normalized to SRC-3+/+ from each feeding regimen and represented as a percentage of wild-type (left panel). Raw run time data from SRC-3+/+ and
SRC-3/ mice (right panel).
(B) Calculated respiratory quotients (VCO2/VO2) obtained from indirect calorimetry measurements from SRC-3
+/+ (white filled, N = 6) and SRC-3/ (black filled,
N = 6) mice run on a 10 incline at 15m/min until exhaustion following a 10-week regimen on SCD. Respiratory quotient data are graphed as a function of total run
time broken into percentage quartiles.
(C) Plasma profiling of b-hydroxybutyrate under resting conditions or immediately following exhaustive exercise in SRC-3+/+ (N = 10) and SRC-3/ (N = 10) mice
fed ad libitum on a 10-week regimen of chow, SCD or LCD.
(D) Measurement of blood glucose in SRC-3+/+ (N = 5) and SRC-3/ (N = 5) mice fed ad libitum following a 10-week regimen of of chow, SCD or LCD.
(E) Quantitative mass spectrometry analysis of AC from skeletal muscle tissue extracts isolated from SRC-3+/+ (N = 5) and SRC-3/ (N = 5) mice fed ad libitum
(white bars) or following a 24 hr fast (black bars) after a 10-week regimen on a SCD. Data are represented as the sum (S) of all long chain species of AC.
(F) Quantitative mass spectrometric analysis of plasma amino acids from SRC-3+/+ (white bars, N = 5) and SRC-3/ (black bars, N = 5) mice following a 10-week
regimen on a SCD. Data are graphed as the mean ± s.e.m. *p < 0.05, **p < 0.01, NS = not statistically significant versus WT mice.
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Figure 5. SRC-3 Regulation of CACT Expression Is Cell Autonomous
(A) Western blot analysis of SRC-3 and b-actin following siRNA knockdown of SRC-3 in C2C12 myoblasts. Protein levels for each treatment were quantitated by
densitometry using Image J software and normalized to b-actin and are indicated numerically under each lane.
(B) Quantitative real-time PCR analysis of CACT (i) and SRC-3 (ii) gene expression in C2C12 myoblasts after transient knockdown with a non-targeting siRNA
(white bars, N = 3) or siRNA against SRC-3 (black bars, N = 3). All expression levels were normalized to 18S rRNA.
(C) Luciferase reporter assays from COS-1 cells transiently transfected with pGL4.10 vector alone (white bar) or pGL4.10-mCACT1128 (995 to +133) luciferase
construct in the absence or presence of SRC-3 (black bar). All luciferase data were normalized to total protein.
(D) Chromatin immunoprecipitation (ChIP) of SRC-3 from C2C12 myoblasts. The amplicon is directed toward a conserved region approximately 650 bp
upstream of the transcriptional start site or at an unconserved region275 bp upstream. All data are presented as relative promoter occupancy of SRC-3 signal
compared to IgG control.
(E) In vivo ChIP of SRC-3 in skeletal muscles isolated fromSRC-3+/+ (N = 3) and SRC-3/ (N = 3)mice fed ad libitum. The amplicon is directed toward a conserved
region approximately650 bp upstream of the transcriptional start site. All data are presented as relative promoter occupancy of SRC-3 signal compared to IgG.
Data are graphed as the mean ± s.e.m. *p < 0.05, **p < 0.01 versus WT mice.
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overexpression of SRC-3 robustly activates transcription of the
CACT promoter (Figure 5C). To identify the transcription factor(s)
(TFs) that SRC-3 cooperates with to regulateCACT gene expres-
sion, we performed an in silico analysis (www.genomatix.de) of
the CACT promoter for TF binding sites and cross-referenced
that information with ChIP-Seq data from the ENCODE database760 Cell Metabolism 15, 752–763, May 2, 2012 ª2012 Elsevier Inc.(genome.ucsc.edu/ENCODE/). Combined, these analyses
identified four putative candidate TFs: HNF1a, HNF4a, RXR/
PPARa and RXR/PPARd. SRC-3 coactivated transcription of
the CACT promoter with each of these TFs (data not shown),
suggesting that in vivo, SRC-3 cooperates with multiple TFs to
maintain CACT gene expression (Iordanidou et al., 2005; Lim
et al., 2004; Soutoglou et al., 2000). To determine if SRC-3
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SRC-3 Is Essential for Fatty Acid Metabolismoccupies the CACT promoter we performed chromatin immuno-
precipitation (ChIP) assays in C2C12 cells using control antibody
(IgG) or antibody specific for SRC-3 (Figure 5D). These data
clearly demonstrate occupancy of SRC-3 at theCACT promoter,
but not at an unconserved adjacent region (Figure 5C). To
confirm these data in vivo, we performed ChIP assays using
skeletal muscles isolated from SRC-3+/+ and SRC-3/ mice
(Figure 5E). Taken together, these results indicate that SRC-3
occupies the CACT promoter and serves a potent coactivator
of CACT gene expression in muscle.
DISCUSSION
In the present study, we applied metabolomics tools to gain
a more in depth understanding of the metabolic functions of
the p160 family of Steroid Receptor Coactivators (SRCs). These
data directed us to a tissue (skeletal muscle) and pathway (long
chain fatty acid catabolism) in which SRC-3 is having key meta-
bolic effects. Mechanistically, SRC-3 performs this function by
serving as a key transcriptional coactivator of CACT, which is
necessary for mitochondrial long chain fatty acid metabolism.
We have shown that loss of SRC-3 leads to a marked deficit of
CACT gene expression, which likely contributes to impaired
mitochondrial entry of long and very long chain fatty acids in
the muscle, resulting in their accumulation. Consequently, loss
of SRC-3 results in a compilation of phenotypes that mimic the
clinical symptoms of CACT deficiency in humans. The clinical
hallmarks ofCACT deficiency arise from a combination of energy
depletion and metabolic toxicity. Mice lacking SRC-3 are unable
to metabolize long chain fatty acids in muscle, which ultimately
accumulate in the muscle and plasma and cannot be used to
generate ATP. The resulting muscle ATP deficit creates an
increased demand for glucose metabolism, which coupled
with the impairment of mitochondrial b-oxidation, leads to hypo-
ketotic hypoglycemia. As a result, SRC-3/ mice display
increased insulin sensitivity as determined by hyperinsuline-
mic/euglycemic clamp, which has been reported in other cases
of impaired fatty acid oxidation (Koves et al., 2008). Unique to
CACT deficiency, we also observe compensatory protein catab-
olism that leads to increases in levels of multiple amino acids,
and an induction in urea cycle activity, which is ultimately insuf-
ficient to prevent hyperammonemia from increased amino acid
catabolism. SRC-3 deficiency also impairs skeletal muscle
performance, and secondarily, cardiac and neurological func-
tion. While it is difficult to pinpoint the exact etiology of these
phenotypes due to the broadmetabolic impact onmultiple tissue
systems (i.e., skeletal muscle versus cardiac muscle), the effects
of this syndrome that arise from loss of SRC-3 situate this impor-
tant coactivator at an essential interface between fuel demand
and utilization.
Our findings suggest that SRC-3 may coordinately govern
diverse metabolic signaling inputs by bridging the transcriptional
gaps between lipid and glucose metabolism. Work from our
laboratory and others have established that disruption of
SRC-3 function or expression is sufficient to confer wholesale
changes in gross metabolic functions, although a metabolomics
approach such as that taken here has not been reported previ-
ously. Our previously published findings demonstrate that loss
of SRC-3 provides protection against high fat diet-inducedCobesity, partially due to an increase in PGC-1 activity (Coste
et al., 2008). While the prior study reported on the role of SRC-3
in energy expenditure (reported as VO2), fat oxidative capacity,
and endurance capability, a direct comparison of those findings
with the current study is not possible because of differences in
data representation, diet (high fat versus normal chow), and
genetic background. With regard to data representation, Coste
et al. reports an increase in VO2 in the SRC-3
/ as evidence
of improved energy expenditure, whereas we represent these
data in terms of respiratory quotient (RQ = VCO2/VO2). It is
important to note that analysis of the VO2 parameter from the
current study is directly in line with the findings of Coste et al.
(data not shown). In addition to the metabolic consequences
arising from ablation of SRC-3, we have reported that alteration
of its post-translational modification code confers onset of
the metabolic syndrome (Coste et al., 2008; York et al., 2010).
Collectively, these disparate phenotypes highlight the broad
metabolic contributions of SRC-3 and implicate this coactivator
as a key player in maintenance of the energy landscape.
At first glance, it is tempting to view the SRCs as simple
generic amplifiers of transcription, but repeatedly it has been
shown that their regulatory potency lies in the physiologic spec-
ificity of their target genes (Chopra et al., 2011; Chopra et al.,
2008; Duteil et al., 2010). Our findings here lend further credence
to this model by demonstrating that SRC-3 does not regulate the
breadth of fatty oxidation genes, but rather specifically controls
the gatekeeper for long chain fatty acid metabolism in muscle,
CACT. This scenario is mirrored by our recent work showing
that loss of SRC-2 mimics the clinical hallmarks of human
glycogen storage disease (type 1a) due to specific impairment
of G6Pase expression, which is necessary for hepatic glucose
production in response to fasting (Chopra et al., 2008). Collec-
tively, these findings compel us to consider the SRCs as putative
polygenic inputs to previously defined metabolic syndromes
with assumed monogenic origins.
Consistent with the hypothesis that SRC-3 is a major regulator
of CACT expression, one might predict that dysfunctional muta-
tions in SRC-3 could account for patients that present with
symptoms of CACT deficiency, but harbor no pathogenic
mutations in the CACT gene. To investigate this possibility, we
identified 24 clinical patients who exhibited CACT deficient-like
symptoms, but failed to show any deleterious mutations in
CACT. In these 24 patients, we sequenced the entire coding
exons and at least 50 base pairs of their flanking intron regions
of the SRC-3 gene (NCOA3). While definitive deleterious muta-
tions were not identified (Table S1), several patients harbored
heterozygous missense variants of unknown clinical signifi-
cance, and a patient had an intronic variant that possibly altered
splicing. In addition, 44% of patients carried heterozygous
deletion of 1 or 3 glutamine residues in the polymorphic poly-
glutamine tract near the C-terminus of SRC-3. While full investi-
gation into themechanistic impact that thesemutations confer to
SRC-3 expression, stability or function is beyond the scope of
the current study, the identification of these genetic variations
in this finite patient population is consistent with a role for
SRC-3 in unexplained cases of fatty acid oxidation disorders.
In addition to these findings, the role of SRC-3 as a platform
coactivator is further supported by the heterogeneity of
transcription factors (TFs) predicted to regulate CACT geneell Metabolism 15, 752–763, May 2, 2012 ª2012 Elsevier Inc. 761
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SRC-3 Is Essential for Fatty Acid Metabolismexpression (i.e., HNF1a, HNF4a, RXR/PPARa and RXR/PPARd)
(Gutgesell et al., 2009; Tachibana et al., 2009), Importantly,
expression levels of these factors are not influenced by loss of
SRC-3 (data not shown). Moreover, our data clearly supports
the occupancy of the CACT promoter by SRC-3, suggesting
that it plays a direct role in regulation of CACT expression. While
it is likely that these TFs respond to multiple signaling inputs to
maintain CACT gene expression, the efficacy of these factors
hinges on the limited availability of SRC-3 to optimally drive
transcription. Therefore, in the case of monogenic diseases
such as CACT deficiency, while loss of a central coactivator
like SRC-3 may not yield a bona fide phenocopy of the human
disease, ablation of SRC-3 is sufficient to mimic the complete
symptoms arising from genetic inactivation of CACT. These find-
ings are of clinical interest because they underscore the SRCs as
potential contributors to the etiology of previously definedmono-
genic diseases.
EXPERIMENTAL PROCEDURES
Animals
All animal experiments were performed in accordance with the Animal Care
Research Committee at Baylor College of Medicine. The generation of the
SRC-1/, SRC-2/, and SRC-3/ mice has been described previously
(Gehin et al., 2002; Qi et al., 1999; Xu et al., 2000). Only male, age-matched
littermate (10-16 weeks old) mice were used. Animals were maintained in
a temperature controlled (23C) facility with a 12 hr light/dark cycle. Mice on
normal chow were fed 2920X Teklad Global rodent ad libitum with free access
to food and water, or fasted for 24 hr with access to water only as indicated.
Separate cohorts of SRC-3+/+ and SRC-3/ littermate male mice were main-
tained on either short chain fatty acid enriched diet (SCD: Harlan Teklad
TD.09849 (1FO: 1 Lard)) or a long chain fatty acid enriched diet (LCD: Harlan
Teklad TD.09848 (1CCO: 1HCCO)) for 10 weeks.
Metabolomic Profiling
Metabolomics analyses have been described in detail elsewhere (An et al.,
2004; Haqq et al., 2005; Newgard et al., 2009). Briefly, amino acids, acyl-carni-
tines and organic acids were measured using stable isotope dilution tech-
niques. Amino acids and acyl-carnitine species were measured using flow
injection tandem mass spectrometry and sample preparation methods
described previously (An et al., 2004; Haqq et al., 2005). Data was acquired
using a Micromass Quattro micro TM system equipped with a model 2777 au-
tosampler, a model 1525 m HPLC solvent delivery system, and a data system
controlled by MassLynx 4.0 operating system (Waters, Milford, MA). Organic
acids were quantified using a previously described method using Trace GC
Ultra coupled to a Trace DSQMSoperating under Excalibur 1.4 (Thermo Fisher
Scientific, Austin, TX). All MS analyses employed stable-isotope-dilution. The
standard allows for identification of each analytes peak, and provides the
reference for quantifying their levels. Quantification was facilitated by addition
of mixtures of known quantities of stable-isotope internal standards to
samples exactly as described (An et al., 2004; Haqq et al., 2005). In addition
to mass, analytes are identified on the basis of the particular MS/MS transi-
tions that we monitor for each class of metabolite.
qPCR Assays
Total mRNA was isolated from muscle or liver using the RNeasy Kit (QIAGEN).
Reverse transcription was carried out using Superscript III (Invitrogen) per
the manufacturer’s instructions. For gene expression analysis, qPCR was
performed using the Taqman system with sequence-specific primers and
the Universal Probe Library (Roche). For all analyses, 18S rRNA was used as
an internal control. Sequences of qPCR primers are available upon request.
Hyperinsulinemic/Euglycemic Clamp
Glucose clamp studies and tissue specific glucose uptake were performed as
previously described (Saha et al., 2004). Briefly, mice were anesthetized and762 Cell Metabolism 15, 752–763, May 2, 2012 ª2012 Elsevier Inc.cannulated followed by a 3-4 day recovery. Mice were fasted overnight then
administered a primed infusion (10 mCi) followed by a constant intravenous
infusion (0.1 mCi/min) of [3-3H]-glucose (Perkin Elmer Life Sciences). Basal
glucose production was measured by tail vein bleed 60 min after glucose
infusion. Mice were then primed with regular insulin (40 millunits/kg BW)
followed by a 2 hr insulin infusion (3 millunitsw/kg/min) while simultaneously
infusing 10% glucose at a rate adjusted to maintain blood glucose between
100-140 mg/dl. Blood glucose concentrations were determined every
10min by a handheld glucometer (Lifescan). Following a 120min period, blood
was collected to determine hepatic glucose production and glucose disposal
rates.
Treadmill Endurance Tests
SRC-3+/+ and SRC-3/ mice were acclimated to treadmill running (5 m/min
for 3 min) prior to testing. For endurance testing, acclimated mice were run
on a treadmill at a 10 incline at a constant speed of 15 m/min until exhaustion.
Statistical Analyses
All results are shown as the mean ± standard error mean (s.e.m.). Standard
statistical comparison of different groups with Gaussian distribution was
carried out using two-tailed unpaired Student’s t test. For analysis of the in vivo
ChIP data, theMann-Whitney U test was used due to a non-Gaussian distribu-
tion and limited sample size. Statistical analysis of area under the curve (AUC)
time-course measurements of glucose and insulin tolerance tests was
performed using a two-way ANOVA (experimental variables = time and geno-
type). For all statistical analyses, differences of p % 0.05 were considered
statistically significant. For all mice studies, the experimental number used is
indicated in each figure legend. For all other studies, experiments were
repeated at least three times.
SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures, one table, Supplemental
Experimental Procedures, and Supplemental References and can be found
with this article online at doi:10.1016/j.cmet.2012.03.020.
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